CN101626685B - N-取代的甘氨酸衍生物：羟化酶抑制剂 - Google Patents
N-取代的甘氨酸衍生物：羟化酶抑制剂 Download PDFInfo
- Publication number
- CN101626685B CN101626685B CN2008800073024A CN200880007302A CN101626685B CN 101626685 B CN101626685 B CN 101626685B CN 2008800073024 A CN2008800073024 A CN 2008800073024A CN 200880007302 A CN200880007302 A CN 200880007302A CN 101626685 B CN101626685 B CN 101626685B
- Authority
- CN
- China
- Prior art keywords
- added
- mmol
- oxo
- dihydro
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCOC(C(C(N(*)N=C1*)=O)=C1O)=O Chemical compound CCOC(C(C(N(*)N=C1*)=O)=C1O)=O 0.000 description 2
- DPECEEYIAVHSFA-UHFFFAOYSA-N CC(C)(C)C(C(O)=C1C(NCC(O)=O)=O)=NN(Cc2ccccc2Br)C1=O Chemical compound CC(C)(C)C(C(O)=C1C(NCC(O)=O)=O)=NN(Cc2ccccc2Br)C1=O DPECEEYIAVHSFA-UHFFFAOYSA-N 0.000 description 1
- JBVRDBFRATUHDD-UHFFFAOYSA-N CC(C)(C)c1ccc(CN2N=C(C3CCCCC3)C(O)=C(C(NCC(O)=O)=O)C2=O)cc1 Chemical compound CC(C)(C)c1ccc(CN2N=C(C3CCCCC3)C(O)=C(C(NCC(O)=O)=O)C2=O)cc1 JBVRDBFRATUHDD-UHFFFAOYSA-N 0.000 description 1
- LLBJXUHJYDBXSZ-UHFFFAOYSA-N CC(C)(C)c1ccc(CN2N=C(c(cc3)ccc3Cl)C(O)=C(C(NCC(O)=O)=O)C2=O)cc1 Chemical compound CC(C)(C)c1ccc(CN2N=C(c(cc3)ccc3Cl)C(O)=C(C(NCC(O)=O)=O)C2=O)cc1 LLBJXUHJYDBXSZ-UHFFFAOYSA-N 0.000 description 1
- RWILEBQJSWJTJX-UHFFFAOYSA-N CC(C)C(C(O)=C1C(NCC(O)=O)=O)=NN(Cc2ccccc2-c2ccccc2)C1=O Chemical compound CC(C)C(C(O)=C1C(NCC(O)=O)=O)=NN(Cc2ccccc2-c2ccccc2)C1=O RWILEBQJSWJTJX-UHFFFAOYSA-N 0.000 description 1
- PBPXHPGOPGLQCP-UHFFFAOYSA-N CC(C)C(C(O)=C1C(NCC(O)=O)=O)=NN(Cc2ccccc2[N+]([O-])=O)C1=O Chemical compound CC(C)C(C(O)=C1C(NCC(O)=O)=O)=NN(Cc2ccccc2[N+]([O-])=O)C1=O PBPXHPGOPGLQCP-UHFFFAOYSA-N 0.000 description 1
- NONSTXILLUFKEK-UHFFFAOYSA-N CCOc1cc(F)cc(C(C(O)=C2C(NCC(O)=O)=O)=NN(Cc3cc(F)cc(F)c3)C2=O)c1 Chemical compound CCOc1cc(F)cc(C(C(O)=C2C(NCC(O)=O)=O)=NN(Cc3cc(F)cc(F)c3)C2=O)c1 NONSTXILLUFKEK-UHFFFAOYSA-N 0.000 description 1
- LYUMRFNFYTZTOG-UHFFFAOYSA-N COc1cccc(C(C(O)=C2C(NCC(O)=O)=O)=NN(Cc3c(C(F)(F)F)cccc3)C2=O)c1 Chemical compound COc1cccc(C(C(O)=C2C(NCC(O)=O)=O)=NN(Cc3c(C(F)(F)F)cccc3)C2=O)c1 LYUMRFNFYTZTOG-UHFFFAOYSA-N 0.000 description 1
- QIFUJJUUMQMROD-UHFFFAOYSA-N OC(CNC(C(C(N(Cc(cc1)ccc1-c1ccccc1)N=C1c(cc2)ccc2F)=O)=C1O)=O)=O Chemical compound OC(CNC(C(C(N(Cc(cc1)ccc1-c1ccccc1)N=C1c(cc2)ccc2F)=O)=C1O)=O)=O QIFUJJUUMQMROD-UHFFFAOYSA-N 0.000 description 1
- FLEMSODDMUWMIV-UHFFFAOYSA-N OC(CNC(C(C(N(Cc1ccccc1C(F)(F)F)N=C1c2cc(F)cc(F)c2)=O)=C1O)=O)=O Chemical compound OC(CNC(C(C(N(Cc1ccccc1C(F)(F)F)N=C1c2cc(F)cc(F)c2)=O)=C1O)=O)=O FLEMSODDMUWMIV-UHFFFAOYSA-N 0.000 description 1
- KDXBFIQIWOGQMC-UHFFFAOYSA-N OC(CNC(C(C(N(Cc1ccccc1Cl)N=C1C2CCCCC2)=O)=C1O)=O)=O Chemical compound OC(CNC(C(C(N(Cc1ccccc1Cl)N=C1C2CCCCC2)=O)=C1O)=O)=O KDXBFIQIWOGQMC-UHFFFAOYSA-N 0.000 description 1
- NQGJCFFOVIOINF-UHFFFAOYSA-N OC(CNC(C(C(NN=C1c2c[nH]c3ccccc23)=O)=C1O)=O)=O Chemical compound OC(CNC(C(C(NN=C1c2c[nH]c3ccccc23)=O)=C1O)=O)=O NQGJCFFOVIOINF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88471007P | 2007-01-12 | 2007-01-12 | |
| US60/884,710 | 2007-01-12 | ||
| PCT/US2008/050833 WO2008089052A2 (en) | 2007-01-12 | 2008-01-11 | N-substituted glycine derivatives: hydroxylase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101626685A CN101626685A (zh) | 2010-01-13 |
| CN101626685B true CN101626685B (zh) | 2013-03-13 |
Family
ID=39636631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008800073024A Expired - Fee Related CN101626685B (zh) | 2007-01-12 | 2008-01-11 | N-取代的甘氨酸衍生物：羟化酶抑制剂 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7608621B2 (https=) |
| EP (2) | EP2124565B1 (https=) |
| JP (1) | JP5313925B2 (https=) |
| KR (1) | KR101458655B1 (https=) |
| CN (1) | CN101626685B (https=) |
| AR (1) | AR064878A1 (https=) |
| AU (1) | AU2008206441B2 (https=) |
| BR (1) | BRPI0806566A2 (https=) |
| CA (1) | CA2675252C (https=) |
| CL (1) | CL2008000066A1 (https=) |
| DK (1) | DK2124565T3 (https=) |
| EA (1) | EA017112B1 (https=) |
| ES (2) | ES2528745T3 (https=) |
| HR (1) | HRP20150119T1 (https=) |
| MX (1) | MX2009007548A (https=) |
| PL (1) | PL2124565T3 (https=) |
| PT (1) | PT2124565E (https=) |
| SI (1) | SI2124565T1 (https=) |
| TW (1) | TW200845991A (https=) |
| WO (1) | WO2008089052A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI336260B (en) * | 2002-07-25 | 2011-01-21 | Glaxo Group Ltd | Dosage form suitable for retaining drug substance |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| ITMI20051085A1 (it) * | 2005-06-10 | 2006-12-11 | Acs Dobfar Spa | Metodo di purificazione del cefotetan |
| US8450351B2 (en) * | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| PL3357911T3 (pl) | 2006-06-26 | 2022-09-05 | Akebia Therapeutics Inc. | Inhibitory prolilohydroksylazy i sposoby ich użycia |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008036642A2 (en) * | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| WO2009100250A1 (en) | 2008-02-05 | 2009-08-13 | Fibrogen, Inc. | Chromene derivatives and use thereof as hif hydroxylase activity inhibitors |
| PT2294066E (pt) | 2008-04-28 | 2014-11-21 | Janssen Pharmaceutica Nv | Benzoimidazoles como inibidores da prolil-hidroxilase |
| JP5465720B2 (ja) | 2008-07-08 | 2014-04-09 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール |
| US8217043B2 (en) | 2008-08-20 | 2012-07-10 | Fibrogen, Inc. | Compounds and methods for their use |
| WO2010025087A1 (en) * | 2008-08-25 | 2010-03-04 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2010055884A1 (ja) * | 2008-11-13 | 2010-05-20 | 日本農薬株式会社 | ピラジン誘導体類の製造方法及びその中間体類 |
| JP5649584B2 (ja) | 2008-11-14 | 2015-01-07 | フィブロジェン インコーポレイテッド | Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体 |
| DE102009004061A1 (de) * | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | Pyridazinonderivate |
| EP3594213A1 (en) * | 2009-07-17 | 2020-01-15 | Japan Tobacco Inc. | Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers |
| WO2011048611A1 (en) * | 2009-10-07 | 2011-04-28 | Torrent Pharmaceuticals Limited | Novel fused pyridazine derivatives |
| KR101665749B1 (ko) * | 2009-10-21 | 2016-10-12 | 다이이찌 산쿄 가부시키가이샤 | 5-하이드록시피리미딘-4-카르복사미드 유도체 |
| RS54010B1 (sr) | 2009-11-06 | 2015-10-30 | Aerpio Therapeutics Inc. | Inhibitori prolil hidroksilaze |
| WO2011115687A2 (en) * | 2010-03-19 | 2011-09-22 | Northwestern University | Alkylated sp-b peptoid compounds and related lung surfactant compositions |
| WO2012106472A1 (en) | 2011-02-02 | 2012-08-09 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase |
| GB201102659D0 (en) | 2011-02-15 | 2011-03-30 | Isis Innovation | Assay |
| NO2686520T3 (https=) | 2011-06-06 | 2018-03-17 | ||
| WO2012170439A1 (en) | 2011-06-06 | 2012-12-13 | The Ohio State University | Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| GB201113101D0 (en) | 2011-07-28 | 2011-09-14 | Isis Innovation | Assay |
| WO2013063221A1 (en) | 2011-10-25 | 2013-05-02 | Janssen Pharmaceutica Nv | Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid |
| TWI583670B (zh) | 2012-07-30 | 2017-05-21 | 大正製藥股份有限公司 | Partially saturated nitrogenous heterocyclic compounds |
| JP2016521747A (ja) | 2013-06-13 | 2016-07-25 | アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 貧血治療のための組成物及び方法 |
| ES2799582T3 (es) | 2013-11-08 | 2020-12-18 | Incyte Holdings Corp | Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa |
| MY180626A (en) | 2013-11-15 | 2020-12-03 | Akebia Therapeutics Inc | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| WO2016034108A1 (zh) | 2014-09-02 | 2016-03-10 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其应用 |
| US10150734B2 (en) | 2015-01-23 | 2018-12-11 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| US11324734B2 (en) | 2015-04-01 | 2022-05-10 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
| CN105130888A (zh) * | 2015-10-09 | 2015-12-09 | 中国药科大学 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
| CA3001065A1 (en) | 2015-10-14 | 2017-04-20 | Xiaoxi WEI | Compositions and methods for reducing ice crystal formation |
| US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| WO2021117767A1 (ja) | 2019-12-10 | 2021-06-17 | 田辺三菱製薬株式会社 | 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法 |
| WO2021127273A1 (en) * | 2019-12-20 | 2021-06-24 | Gb004, Inc. | 1 -((6-oxo-1,6-dihydropyridazin-4-yl)methyl)piperazine and 1 -((6-oxo-1,6-dihydropyrimidin-4-yl)methyl)piperazine derivatives as prolyl hydroxylase, hif-1 alpha and pgk modulators for use in treating inflammatory diseases, cancer or infections |
| WO2022179967A1 (en) | 2021-02-23 | 2022-09-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Vadadustat for treating covid-19 in a hospitalized subject |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1107144A (zh) * | 1993-11-02 | 1995-08-23 | 赫彻斯特股份公司 | 取代的杂环羧酰胺酯，它们的制备及它们作为药物的用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
| GB9507318D0 (en) * | 1995-04-07 | 1995-05-31 | Zeneca Ltd | Alpha substituted pyridazino quinoline compounds |
| US6972296B2 (en) * | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| DE10059418A1 (de) | 2000-11-30 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| DK2298301T3 (en) | 2001-12-06 | 2018-10-01 | Fibrogen Inc | MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease |
| US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| AU2003225088A1 (en) | 2002-04-19 | 2003-11-03 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| US7718624B2 (en) | 2004-09-01 | 2010-05-18 | Sitkovsky Michail V | Modulation of immune response and inflammation by targeting hypoxia inducible factors |
| EP1655283A1 (en) | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
| AU2006254897A1 (en) * | 2005-06-06 | 2006-12-14 | Fibrogen, Inc. | Improved treatment for anemia using a HIF-alpha stabilising agent |
| US7713986B2 (en) | 2006-06-15 | 2010-05-11 | Fibrogen, Inc. | Compounds and methods for treatment of chemotherapy-induced anemia |
| US20070293575A1 (en) | 2006-06-15 | 2007-12-20 | Fibrogen, Inc. | Compounds and methods for treatment of cancer-related anemia |
| HRP20130044T1 (hr) | 2006-07-25 | 2013-02-28 | Cephalon, Inc. | Derivati piridizinona |
| WO2008040002A2 (en) | 2006-09-28 | 2008-04-03 | Fred Hutchinson Cancer Research Center | Methods, compositions and articles of manufacture for hif modulating compounds |
| US20100003190A1 (en) | 2006-12-08 | 2010-01-07 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN) |
| WO2009142732A2 (en) | 2008-05-20 | 2009-11-26 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
-
2008
- 2008-01-10 TW TW097100936A patent/TW200845991A/zh unknown
- 2008-01-10 CL CL200800066A patent/CL2008000066A1/es unknown
- 2008-01-11 EA EA200970680A patent/EA017112B1/ru not_active IP Right Cessation
- 2008-01-11 ES ES08727581.4T patent/ES2528745T3/es active Active
- 2008-01-11 MX MX2009007548A patent/MX2009007548A/es active IP Right Grant
- 2008-01-11 AR ARP080100143A patent/AR064878A1/es active IP Right Grant
- 2008-01-11 HR HRP20150119TT patent/HRP20150119T1/hr unknown
- 2008-01-11 US US11/972,702 patent/US7608621B2/en not_active Ceased
- 2008-01-11 CN CN2008800073024A patent/CN101626685B/zh not_active Expired - Fee Related
- 2008-01-11 DK DK08727581.4T patent/DK2124565T3/en active
- 2008-01-11 ES ES14196983.2T patent/ES2614355T3/es active Active
- 2008-01-11 AU AU2008206441A patent/AU2008206441B2/en not_active Ceased
- 2008-01-11 SI SI200831409T patent/SI2124565T1/sl unknown
- 2008-01-11 EP EP08727581.4A patent/EP2124565B1/en active Active
- 2008-01-11 CA CA2675252A patent/CA2675252C/en active Active
- 2008-01-11 EP EP14196983.2A patent/EP2889289B1/en not_active Not-in-force
- 2008-01-11 PL PL08727581T patent/PL2124565T3/pl unknown
- 2008-01-11 PT PT08727581T patent/PT2124565E/pt unknown
- 2008-01-11 KR KR1020097016748A patent/KR101458655B1/ko active Active
- 2008-01-11 JP JP2009545699A patent/JP5313925B2/ja not_active Expired - Fee Related
- 2008-01-11 BR BRPI0806566-7A patent/BRPI0806566A2/pt not_active IP Right Cessation
- 2008-01-11 WO PCT/US2008/050833 patent/WO2008089052A2/en not_active Ceased
-
2011
- 2011-10-26 US US13/281,965 patent/USRE44613E1/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1107144A (zh) * | 1993-11-02 | 1995-08-23 | 赫彻斯特股份公司 | 取代的杂环羧酰胺酯，它们的制备及它们作为药物的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| USRE44613E1 (en) | 2013-11-26 |
| ES2614355T3 (es) | 2017-05-30 |
| US20080214549A1 (en) | 2008-09-04 |
| AU2008206441A1 (en) | 2008-07-24 |
| CN101626685A (zh) | 2010-01-13 |
| JP2010515756A (ja) | 2010-05-13 |
| SI2124565T1 (sl) | 2015-04-30 |
| US7608621B2 (en) | 2009-10-27 |
| EP2124565B1 (en) | 2015-01-07 |
| PT2124565E (pt) | 2015-03-26 |
| AR064878A1 (es) | 2009-04-29 |
| BRPI0806566A2 (pt) | 2014-05-06 |
| EP2889289A1 (en) | 2015-07-01 |
| CL2008000066A1 (es) | 2008-08-01 |
| WO2008089052A2 (en) | 2008-07-24 |
| EA200970680A1 (ru) | 2010-02-26 |
| EP2889289B1 (en) | 2016-12-21 |
| KR20090101376A (ko) | 2009-09-25 |
| KR101458655B1 (ko) | 2014-11-05 |
| HRP20150119T1 (hr) | 2015-05-08 |
| EA017112B1 (ru) | 2012-09-28 |
| EP2124565A2 (en) | 2009-12-02 |
| MX2009007548A (es) | 2009-07-22 |
| EP2124565A4 (en) | 2011-06-29 |
| JP5313925B2 (ja) | 2013-10-09 |
| CA2675252C (en) | 2015-05-26 |
| DK2124565T3 (en) | 2015-02-09 |
| PL2124565T3 (pl) | 2015-05-29 |
| ES2528745T3 (es) | 2015-02-12 |
| TW200845991A (en) | 2008-12-01 |
| AU2008206441B2 (en) | 2014-06-19 |
| CA2675252A1 (en) | 2008-07-24 |
| WO2008089052A3 (en) | 2008-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101626685B (zh) | N-取代的甘氨酸衍生物：羟化酶抑制剂 | |
| CN101505752B (zh) | 脯氨酸羟化酶抑制剂 | |
| CN102365277B (zh) | Jun n-末端激酶抑制剂 | |
| JP5758630B2 (ja) | Ｐａｒｐ阻害剤としてのピリダジノン誘導体 | |
| TWI418555B (zh) | 新穎脯胺酸衍生物 | |
| CN1832928B (zh) | 以5元杂环为基础的p38激酶抑制剂 | |
| KR100666838B1 (ko) | 프로스타글란딘 엔도퍼옥사이드 ｈ 신타제 생합성 억제제 및 이를 포함하는 약제학적 조성물 | |
| CN115850268A (zh) | 作为cftr增效剂的吡咯并嘧啶 | |
| EP1881977A1 (en) | Histone deacetylase inhibitors | |
| JP2007519692A (ja) | ｐ３８キナーゼ阻害剤として使用するための縮合ヘテロアリール誘導体 | |
| RS54369B1 (sr) | Nova jedinjenja hinolina supstituisana kao inhibitori s-nitrosoglutathione reduktaze | |
| US20110144167A1 (en) | Prolyl Hydroxylase Inhibitors | |
| CN111566103A (zh) | 作为激酶抑制剂的氨基咪唑并吡嗪 | |
| JP2021525728A (ja) | Ｍａｓｐ−２阻害剤および使用方法 | |
| AU2017290705A1 (en) | Compounds and compositions for the treatment of cancer | |
| JP5490113B2 (ja) | 置換１−ベンジル−シンノリン−４（１ｈ）−オン誘導体、この調製、およびこの治療的使用 | |
| CN117430589A (zh) | 2-氨基嘧啶类化合物或其盐及其制备方法和用途 | |
| HK1159109A (en) | Substituted 1-benzyl-cinnolin-4(1h)-one derivatives, preparation thereof, and therapeutic use thereof | |
| HK1216533B (zh) | Bace1抑制剂 | |
| BRPI0820236B1 (pt) | Compostos derivados de piridazinona, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130313 |